Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy.
A method has been devised for evaluating the rate and extent of regression of the first 100 consecutive patients with a posterior uveal melanoma that we had managed by Cobalt-60 plaque radiotherapy at Wills Eye Hospital. It was found that the "average" posterior uveal melanoma in the series did not regress rapidly to a flat, depigmented scar but shrank slowly and persisted as a residual mass approximately 50% of the thickness of the original tumor at 54 months following Cobalt-60 plaque radiotherapy. We also found that the rate and extent of regression of the tumors in patients who subsequently developed metastatic melanoma were not appreciably different than the rate and extent of regression of the tumors in patients who remained well systemically. These observations indicate that the rate and extent of regression of posterior uveal melanomas following Cobalt-60 plaque radiotherapy are poor indicators of the prognosis of the affected patients for subsequent development of clinical metastatic disease.
D001918:Brachytherapy; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy* / Q000556:secondary; D011379:Prognosis; D013997:Time Factors; D014604:Uveal Neoplasms / Q000532:radiotherapy*
D003037:Cobalt Radioisotopes